ID   UCD65
AC   CVCL_ZV44
DR   cancercelllines; CVCL_ZV44
DR   Wikidata; Q98133840
RX   PubMed=32576280;
CC   Characteristics: Established from a patient-derived xenograft.
CC   Characteristics: ER/PR-positive and ERBB2-negative.
CC   Doubling time: 132.8 hours, 109.3 hours (Note=With 17-beta-estradiol) (PubMed=32576280).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; p.Leu792fs*2 (c.2372dupT); Zygosity=Unspecified (PubMed=32576280).
CC   Sequence variation: Mutation; HGNC; HGNC:7882; NOTCH2; Simple; p.Leu2135Glufs*2 (c.6403_6404delCT); ClinVar=VCV000946387; Zygosity=Unspecified (PubMed=32576280).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 10-04-25; Version: 10
//
RX   PubMed=32576280; DOI=10.1186/s13058-020-01300-y; PMCID=PMC7310532;
RA   Finlay-Schultz J., Jacobsen B.M., Riley D., Paul K.V., Turner S.,
RA   Ferreira-Gonzalez A., Harrell J.C., Kabos P., Sartorius C.A.;
RT   "New generation breast cancer cell lines developed from
RT   patient-derived xenografts.";
RL   Breast Cancer Res. 22:68.1-68.12(2020).
//